Kalmente (Mometasone Furoate Anhydrous)

Mometasone furoate binds to glucocorticoid receptors in nasal tissues, altering gene transcription to suppress the production of inflammatory cytokines and mediators. This reduces swelling, mucus production, and other inflammatory signs in the nasal passages.

The specific dose and frequency of Kalmente are determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Kalmente.

To request Kalmente, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kalmente (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with older agents such as beclomethasone, it offers once‑daily dosing and strong anti‑inflammatory activity, making it a preferred option for many clinicians.

Kalmente should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not freeze the product, and keep the spray cap tightly closed when not in use.

Kalmente is administered as a nasal spray. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The same procedure is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, adrenal suppression with prolonged high‑dose use, increased intra‑ocular pressure leading to glaucoma, and severe allergic reactions. Patients should report any unusual symptoms such as persistent nosebleeds, vision changes, or signs of systemic steroid effects.

Kalmente should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. Caution is also advised for patients with active untreated fungal, bacterial, or viral infections of the nasal passages, and those who have recently received live vaccines.